MoonLake Immunotherapeutics shares surged 31% after the Financial Times reported, citing unnamed sources, that the company had rejected an initial acquisition offer by Merck & Co. for more than $3 ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...

MoonLake Immunotherapeutics' Sonelokimab's Phase 3 trials, PsA market growth, and Merck's $3B bid showcase potential. Read my ...

Stocks were rising Tuesday and the Nasdaq Composite turned higher for the year even as uncertainty over global trade ...

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it ...

Despite the slowdown in dealmaking, French drugmaker Sanofi on Monday agreed to buy immunology-focused biotech Blueprint Medicines in a deal worth up to $9.5bn and Bristol Myers Squibb struck an up to ...

In trading on Tuesday, shares of MoonLake Immunotherapeutics (Symbol: MLTX) crossed above their 200 day moving average of $45.66, changing hands as high as $49.48 per share. MoonLake ...

MoonLake Immunotherapeutics has announced the initiation of new trials for sonelokimab, an investigational Nanobody® aimed at treating inflammatory diseases. The Phase 3 VELA-TEEN trial will ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

MERCK has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than US$3 billion, the Financial Times ...